Audentes CEO exits as Astellas rebrands a gene therapy buyout

Audentes CEO exits as Astellas rebrands a gene therapy buyout

Source: 
BioPharma Dive
snippet: 

Natalie Holles, the chief executive of Audentes Therapeutics, has departed the company as the gene therapy developer's new owner Astellas Pharma fully folds the biotech into its larger organization.

Audentes, which was acquired by Astellas for $3 billion almost a year and a half ago, will now operate under the name Astellas Gene Therapies, the company announced Wednesday.